Abstract
We investigate a mathematical model using a system of coupled ordinary differential equations, which describes the interplay of malignant glioma cells, macrophages, glioma specific CD8+T cells and the immunotherapeutic drug Adoptive Cellular Immunotherapy (ACI). To better understand under what circumstances the glioma cells can be eliminated, we employ the theory of optimal control. We investigate the dynamics of the system by observing biologically feasible equilibrium points and their stability analysis before administration of the external therapy ACI. We solve an optimal control problem with an objective functional which minimizes the glioma cell burden as well as the side effects of the treatment. We characterize our optimal control in terms of the solutions to the optimality system, in which the state system coupled with the adjoint system. Our model simulation demonstrates that the strength of treatment
Acknowledgements
I am thankful to the reviewer and the editor for their careful reading of this manuscript, the questions they posed and suggestions they offered. As a result, this paper is significantly improved. This study was supported by the Science & Engineering Research Board (SERB), Govt. of India, File No.: ECR/2017/000234.
References
[1] L.M. DeAngelis, Brain tumors, N. Engl. J. Med. 344 (2001), 114–123.10.1056/NEJM200101113440207Search in Google Scholar PubMed
[2] G.P. Dunn, L.J. Old and R.D. Schreiber, The three Es of cancer immunoediting, Annu. Rev. Immunol. 22 (2004), 329–360.10.1146/annurev.immunol.22.012703.104803Search in Google Scholar PubMed
[3] S. Khajanchi, Bifurcation analysis of a delayed mathematical model for tumor growth, Chaos Solitons Fractals. 77 (2015), 264–276.10.1016/j.chaos.2015.06.001Search in Google Scholar
[4] P. Gerlee and S. Nelander, The impact of phenotypic switching on glioblastoma growth and invasion, PLoS ONE Comput. Biol. 8(6) (2012), e1002556.10.1371/journal.pcbi.1002556Search in Google Scholar PubMed PubMed Central
[5] N. Kronik, Y. Kogan, V. Vainstein and Z. Agur, Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics, Cancer Immunol. Immunother. 57(3) (2008), 425–439.10.1007/s00262-007-0387-zSearch in Google Scholar PubMed
[6] S. Nandi, S. Khajanchi, A.N. Chatterjee and P.K. Roy, Insight of viral infection of Jatropha Curcas plant (future fuel): a control based mathematical study, Acta Anal. Funct. Appl. 13(4) (2011), 366–374.Search in Google Scholar
[7] S. Khajanchi, Modeling the dynamics of glioma-immune surveillance, Choas Solitons Fractals. 114 (2018), 108–118.10.1016/j.chaos.2018.06.028Search in Google Scholar
[8] M. Gosak, R. Markovic, J. Dolensek, M.S. Rupnik, M. Marhl, A. Stozer and M. Perc, Network science of biological systems at different scales: a review, Phys. Life Rev. 24 (2018), 118–135.10.1016/j.plrev.2017.11.003Search in Google Scholar PubMed
[9] S. Banerjee, S. Khajanchi and S. Chaudhury, A mathematical model to elucidate brain tumor abrogration by immunotherapy with T11 target struncture, PLoS ONE 10(5) (2015), e0123611.10.1371/journal.pone.0123611Search in Google Scholar PubMed PubMed Central
[10] K.R. Swanson, C. Bridge, J.D. Murray and E.C. Alvord Jr, Virtual and real brain tumors: Using mathematical modeling to quantify glioma growth invasion, J. Neurol. Sci. 216(1) (2003), 1–10.10.1016/j.jns.2003.06.001Search in Google Scholar PubMed
[11] R.D. Schreiber, L.J. Old and M.J. Smyth, Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion, Science 331 (2011), 1565–1570.10.1126/science.1203486Search in Google Scholar PubMed
[12] W.F. Hickey, Basic principles of immunological surveillance of the normal central nervous system, Glia 36 (2001), 118–124.10.1002/glia.1101Search in Google Scholar PubMed
[13] S. Khajanchi and S. Banerjee, Stability and bifurcation analysis of delay induced tumor immune interaction model, Appl. Math. Comput. 248 (2014), 652–671.10.1016/j.amc.2014.10.009Search in Google Scholar
[14] S. Khajanchi and J.J. Nieto, Mathematical modeling of tumor-immune competitive system, considering the role of time delay, Appl. Math. Comput. 340 (2019), 180–205.10.1016/j.amc.2018.08.018Search in Google Scholar
[15] D. Ghosh, S. Khajanchi, S. Mangiarotti, F. Denis, S.K. Dana and C. Letellier, How tumor growth can be influenced by delayed interactions between cancer cells and the microenvironment?, BioSystems. 158 (2017), 17–30.10.1016/j.biosystems.2017.05.001Search in Google Scholar PubMed
[16] S. Khajanchi and D. Ghosh, The combined effects of optimal control in cancer remission, Appl. Math. Comput. 271 (2015), 375–388.10.1016/j.amc.2015.09.012Search in Google Scholar
[17] V.A. Kuznetsov, I.A. Makalkin, M.A. Taylor and A.S. Perelson, Non-linear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis, Bull. Math. Biol. 56(2) (1994), 295–321.10.1007/BF02460644Search in Google Scholar PubMed
[18] S. Bunimovich-Mendrazitsky, J.C. Gluckman and J. Chaskalovic, A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer, J. Theor. Biol. 277 (2011), 27–40.10.1016/j.jtbi.2011.02.008Search in Google Scholar PubMed
[19] S. Bunimovich-Mendrazitsky, H. Byrne and L. Stone, Mathematical model of pulsed immunotherapy for superficial bladder cancer, Bull. Math. Biol. 70(7) (2008), 2055–2276.10.1007/s11538-008-9344-zSearch in Google Scholar PubMed
[20] X. Lai and A. Friedman, Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs, J. Theor. Biol. 462 (2019), 490–498.10.1016/j.jtbi.2018.11.018Search in Google Scholar PubMed
[21] S. Khajanchi, M. Perc and D. Ghosh, The influence of time delay in a chaotic cancer model, Chaos. 28 (2018), 103101.10.1063/1.5052496Search in Google Scholar PubMed
[22] S. Khajanchi and S. Banerjee, Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: mathematical modeling and dynamical perspective, Math. Biosci. 289 (2017), 69–77.10.1016/j.mbs.2017.04.006Search in Google Scholar
[23] S. Khajanchi, Bifurcations and oscillatory dynamics in a tumor immune interaction model, BIOMAT 2015. (2016), 241–259. doi.org/10.1142/9789813141919\_0016Search in Google Scholar
[24] S.P. Chakrabarty and F.B. Hanson, Distributed parameters deterministic model for treatment of brain tumors using Galerkin finite element method, Math. Biosci. 219 (2009), 129–141.10.1016/j.mbs.2009.03.005Search in Google Scholar
[25] K.C. Iarosz, F.S. Borges, A.M. Batista, M.S. Baptista, R.A.N. Siqueira, R.L. Viana and S.R. Lopes, Mathematical model of brain tumour with glia–neuron interactions and chemotherapy treatment, J. Theor. Biol. 368 (2015), 113–121.10.1016/j.jtbi.2015.01.006Search in Google Scholar
[26] S. Khajanchi and S. Banerjee, Influence of multiple delays in brain tumor and immune system interaction with T11 target structure as a potent stimulator, Math. Biosci. 302 (2018), 116–130.10.1016/j.mbs.2018.06.001Search in Google Scholar
[27] S. Khajanchi, Uniform persistence and global stability for a brain tumor and immune system interaction, Biophys. Rev. Lett. 12(4) (2017), 187–208.10.1142/S1793048017500114Search in Google Scholar
[28] J.M. Murray, Optimal control for a Cancer chemotherapy problem with general growth and loss functions, Math. Biosci. 98(2) (1990), 273–287.10.1016/0025-5564(90)90129-MSearch in Google Scholar
[29] G.W. Swan, General applications of optimal control theory in cancer chemotherapy, IMA J. Math. Appl. Med. Biol. 5(4) (1988), 303–316.10.1093/imammb/5.4.303Search in Google Scholar
[30] G.W. Swan, Role of optimal control theory in Cancer chemotherapy, Math. Biosci. 101(2) (1990), 237–284.10.1016/0025-5564(90)90021-PSearch in Google Scholar
[31] Z. Wang, C.T. Bauch, S. Bhattacharyya, A. d’Onofrio, P. Manfredi, M. Perc, N. Perra, M. Salathe and D. Zhao, Statistical physics of vaccination, Phys. Rep. 664 (2016), 1–113.10.1016/j.physrep.2016.10.006Search in Google Scholar
[32] T. Burden, J. Ernstberger and K.R. Fister, Optimal control applied to immunotherapy, Discrete Cont. Dyn. B 4(1) (2004), 135–146.10.3934/dcdsb.2004.4.135Search in Google Scholar
[33] F. Castiglione and P. Piccoli, Cancer immunotherapy, mathematical modeling and optimal control, J. Theor. Biol. 247(4) (2007), 723–732.10.1016/j.jtbi.2007.04.003Search in Google Scholar
[34] L.G. de Pillis, W. Gu, K.R. Fister, T. Head, K. Maples, A. Murugan, T. Neal and K. Yoshida, Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls, Math. Biosci. 209(1) (2007), 292–315.10.1016/j.mbs.2006.05.003Search in Google Scholar
[35] K.R. Fister and J.C. Panetta, Optimal control applied to competing chemotherapeutic cell-kill strategies, SIAM J. Appl. Math. 63(6) (2003), 1954–1971.10.1137/S0036139902413489Search in Google Scholar
[36] K.R. Fister and J.H. Donnelly, Immunotherapy: An optimal control theory apprach, Math. Biosci. Eng. 2(3) (2005), 499–510.10.3934/mbe.2005.2.499Search in Google Scholar
[37] F.H. Igney and P.H. Krammer, Immune escape of tumors: Apoptosis resistance and tumor counterattack, J. Leukoc. Biol. 71(6) (2002), 907–920.10.1189/jlb.71.6.907Search in Google Scholar
[38] S. Lenhart and J.T. Workman, Optimal control applied to biological models, Chapman and Hall/CRC, 2007.10.1201/9781420011418Search in Google Scholar
[39] L.S. Pontryagin, V.G. Boltyanskii, R.V. Gamkrelidze and E.F. Mishchenko, The mathematical theory of optimal process, Wiley, New Jersey, 1962.Search in Google Scholar
[40] J.S. Spratt and J.A. Meyer, Rates of growth of human neoplasms: Part II, J. Surg. Oncol. 61 (1996), 68–83.10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-ESearch in Google Scholar
© 2019 Walter de Gruyter GmbH, Berlin/Boston
